On 9 December 2025, a quiet but meaningful milestone unfolded at Southampton General Hospital, one of the United Kingdom’s leading oncology centres.
There, clinicians delivered the country’s first commercial treatment using the Australian-developed OncoSil device. This moment marked not only a step forward for patients with locally advanced pancreatic cancer, but the beginning of a new commercial chapter for OncoSil Medical (ASK:OSL).
The Sydney-based medical device company has focused on developing localised treatment options for patients with unresectable locally advanced pancreatic cancer (LAPC), a particularly challenging and often devastating diagnosis. While the device has been evaluated in clinical settings, including the hospital’s participation in the TRIPP-FFX study, the Southampton procedure marks a transition from research to real-world clinical adoption.
Pancreatic cancer remains one of the most aggressive forms of the disease, and demand for new therapies is significant. According to GLOBOCAN data, more than 11,800 people in the UK are diagnosed with pancreatic cancer each year. Of those, OncoSil Medical estimates that roughly 30 per cent, about 3,600 patients, present with locally advanced disease and could be eligible for treatment with the OncoSil device.
OncoSil Medical’s CEO and Managing Director, Nigel Lange, said, “This first commercial treatment in the UK is an important step forward for OncoSil and for patients living with pancreatic cancer,” Lange said. “Southampton General Hospital has long been recognised for its excellence in oncology, and we are proud to see the OncoSil device now being used in such a leading centre. This milestone marks the beginning of our commercial journey in the UK, which we believe represents an addressable market opportunity of $138 million per annum and reinforces our commitment to expanding access to innovative treatment options for patients around the world.”